In patients with high-grade serous ovarian carcinoma who received standard-of-care therapy, p53 alterations identified using ctDNA analysis at baseline were correlated with volume of disease, and a decrease in TP53 mutant allele fraction ≤60% after 1 cycle of chemotherapy was associated with shorter time to disease progression [75]. Here, TP53 is linked to ovarian serous carcinoma.